Malignant Mesothelioma - DOAJ

The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma

In several tumor models, including malignant mesothelioma, Ranpirnase has demonstrated antitumor activity both in vitro and in vivo. Ranpirnase has disease-modifying activity against mesothelioma, according to a large phase II trial. According to a first phase III report, rampirnase can be mixed with doxorubicin, and that such an association is more influential than Ranpirnase alone against mesothelioma.

Source link: https://doaj.org/article/84b5497be7ce42c2bcdc1545ed84c7ea

The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma

Ranpirnase has disease-modifying activity against mesothelioma, according to a large phase II trial. rampirnase can be mixed with doxorubicin, revealing that such an association is more effective than Ranpirnase alone against mesothelioma. Ranpirnase is a popular drug to try in MMe as well as other tumor types due to a better understanding of its mechanism of action and its low toxicity profile, particularly in the absence of major hematologic toxicities.

Source link: https://doaj.org/article/b6ac5a55594c4958914febac8fb9912f

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions